Immuron (IMRN) has disclosed a new risk, in the Accounting & Financial Operations category.
Immuron faces a substantial business risk if it fails to adhere to the Sarbanes-Oxley Act’s stringent internal control and accounting procedures. Despite current compliance, the discovery of material weaknesses or significant deficiencies in the future could undermine investor confidence, leading to a sharp decline in the company’s share and ADS prices. This, in turn, would complicate the company’s efforts to secure capital, potentially stymieing growth and harming its overall financial stability. Effective internal controls are crucial for Immuron to maintain accurate financial reporting and prevent fraudulent activities that could damage its reputation and operational results.
The average IMRN stock price target is $5.00, implying 82.64% upside potential.
To learn more about Immuron’s risk factors, click here.
